HOME > BUSINESS
BUSINESS
- Taiho’s TS-1 Launched in UK, Approved in Hong Kong
April 12, 2012
- Toyota Tsusho Signs Agreement with Korean Venture to Become Sole Agent in Japan
April 12, 2012
- Sanofi Pasteur Targets Double Sales in Japan, Enters 4 Products Including IPV
April 11, 2012
- Takeda Pharmaceutical to Be Refunded 57.1 Bil. Yen for Transfer Pricing Taxation
April 11, 2012
- Sales Level Off for Year Ended Feb 2012 on Effects of Earthquake: Hisamitsu
April 11, 2012
- Sales of Ethical Drugs Up 8.7% in February: Crecon Report
April 10, 2012
- GSK Ties Up with Chiome for Antibody Generation Technology
April 10, 2012
- Fuso, Kaken to Jointly Market Topical Hemostatic Agent
April 10, 2012
- Ethical Drug Production in 2019 Predicted at 11 Trillion Yen: Yano Research Survey
April 10, 2012
- Anticoagulant Market to Heat Up with Lifting of Ban on Long-term Prescription of Prazaxa, Debut of New Products
April 10, 2012
- Generics Made in India to Storm Japanese Market with Overwhelming Price Advantage
April 10, 2012
- Bayer Yakuhin to Focus on 2 Prospective Blockbusters, Target 200 Billion Yen in Sales in 2013: President Guth
April 9, 2012
- US FDA Recommends Approval of Mirabegron from Astellas
April 9, 2012
- Sanofi-aventis, Alfresa Agree on Joint Development of Antiepileptic Drug
April 9, 2012
- Ohara Pharmaceutical Begins Development of Glucarpidase, Aims to File for Approval in 2014
April 9, 2012
- Eisai Establishes Aricept Director Position
April 6, 2012
- MTPC Complements Alliance with BIKEN to Establish Its Own Vaccine Development Infrastructure
April 6, 2012
- BMKK Posts 1st Increase in Sales Since 2005: President & CEO Emmanuel Blin
April 6, 2012
- Eisai Signs Agreement on Marketing Halaven in 8 Central and Eastern European Countries
April 6, 2012
- Toray Grants German Company Marketing Rights for Antipruritic Agent in Europe
April 6, 2012
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…